Loading clinical trials...

Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate | Clinical Trials | Clareo Health

COMPLETED

Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate

NCT03460873•Samsung Medical Center

View on ClinicalTrials.gov

Summary

Prognostic factor in the patients with benign prostatic hyperplasia (BPH) who undergo holmium laser enucleation of the prostate

Eligibility

Age

All ages

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Male patient scheduled to undergo prostatectomy using holmium laser

Exclusion Criteria

•Urethral stricture, large bladder diverticulum, bladder neck contracture

Locations (1)

Samsung Medical Center, Sungkyunkwan University School of Medicine

Seoul, South Korea

Key Dates

Start Date

September 1, 2015

Primary Completion Date

November 7, 2019

Completion Date

November 28, 2019

Last Updated

December 2, 2019

Enrollment

432

ACTUAL participants

Conditions

Benign Prostatic Hyperplasia (BPH)

Interventions

holmium laser enucleation of the prostate

PROCEDURE

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

NCT07016620

Benign Prostatic Hyperplasia (BPH)

View study

RECRUITINGNA

Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging

NCT06817733

Benign Prostatic Hyperplasia (BPH)

View study

COMPLETEDNA

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02026908

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate

Inclusion Criteria

Exclusion Criteria

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

Study of Median Lobe Prostatic UroLift Procedure